Both metrics are based on similar principles: the number of citations received by a journal in a given year to papers published in a given period of time, over the number of papers published by that journal in that time period. A primary difference between these two metrics is the period of time for the calculation; while the Journal Impact Factor calculates the metric using the two previous years as a basis for the citation count, CiteScore uses a three-year period. The time period to compute the citations received is relevant because of the different citation half-lives between scientific disciplines. Areas such as Immunology or Genetics and Molecular Biology cite a substantially greater proportion of articles in the two-year window than papers in Arts and Humanities or Social Sciences. 9 Citations received for a paper published beyond the computing window are ignored in these two metrics. This means that papers published in 2018 will not influence the Journal Impact Factor citing papers published in or before 2015 or the CiteScore citing articles published in or before 2014. While "today's newspaper wraps tomorrow's fish", should we support the idea that today's articles will be ignored in two or three years? Journal Citation Reports provided a partial solution with the 5-year Impact Factor, which computes a five-year window. This computing window may not be sufficient for pharmacy, with a cited half-life of more than 7.5 years (e.g., Am J Health Syst Pharm 7.8; J Am Pharm Assoc 9.3).
The update frequency is something the two metrics have in common; both metrics are calculated and published yearly. A component in favor of CiteScore is the CiteScore Tracker, which is a monthly release of a provisional calculation. Publication frequency should not be synonymous with potential modifications in either metric. CiteScore cannot modify the data published until the next publication, even when an error is identified.
A major difference between the two metrics is the transparency in their calculations. Journal Impact Factor was blamed as being opaque because the calculations are "based on hidden data". 10 The quality of the data used to calculate the Impact Factor was criticized even by high Impact Factor journals. 11 The most intriguing situation is why one cannot easily access the complete list of cited and citing records used to calculate a given Impact Factor, even with full access to the Web of Science. This issue was solved in CiteScore, since citing and cited documents are available through a onelink distance for a Scopus-subscribing institution or individual.
In addition to the lack of transparency, another major difference between the two metrics is the famous denominator, which is the number of articles published by the journal in the given period of time. It might sound strange that scientometricians have difficulties identifying the number of articles published by a journal in a year. This occurs when we add the adjective "citable" to the term "item". What is a citable item? As far as we know, journals' instructions to authors do not prevent citing any kind of contribution. Since the 1980s, Journal Impact Factor calculations have defined the denominator by using an algorithm to identify what they called "meaty" items that "contain substantive research". This algorithm is based on a number of criteria to allocate "points" to the contribution, as a proxy for "the amount and type of information the article contains". Regardless of the contribution's content, the number of authors, references and pages are used to identify what counts in the denominator of the Impact Factor calculations. The consequence of this correction to the simple calculation is that journals' publishing policies have a tremendous impact on Impact Factor. 12 Journal coverage is another difference between the two metrics. Almost 11,000 journals compared to almost 23,000 journals are figures that speak for themselves. The Web of Science bases their "why to be selective" on Bradford's Law. 13 Journal restriction could be a reasonable procedure in the 1950s, when computers and computing power had serious limitations. Limiting the number of journals covered due to the reason "this is a well-covered category" is not acceptable in the "big data age". What does "a well-covered category" mean? The 2016 Journal Citation Reports comprises 228 Subject Categories with a median of 62 journals per category. Should Andrology be considered a "wellcovered category" with 5 journals, when Economics has 347 journals? Despite the greater coverage of CiteScore, journal selection criteria are also not perfect. Apart from several quality-related criteria (e.g., journal policy, content, regularity), Scopus uses other criteria to re-evaluate journals. Among these criteria, citation rate or clicks on scopus.com (all of them if lower than 50% of the average in the field) would be reasons to be excluded from the Scopus catalog and subsequently from the CiteScore analysis.
14 This leads to another major difference between the two metrics that carries enormous relevance for our research area: the definition of Subject Area, as named by CiteScore, or Subject Category, following the Journal Citation Reports terminology. The definition of sister journals is crucial because bibliometric indexes only can be compared among analogous components by using the quartile distribution as a simple metric. To do this, each of these metrics classifies the journals among categories that represent areas of knowledge and research. The Journal Citation Reports includes pharmacy journals in the Subject Category of Pharmacology & Pharmacy, which comprises 257 journals ranging from a 57.000 to a 0.035 Impact Factor in the 2016 edition. The Pharmacology & Pharmacy Subject Category was criticized as heterogeneous because it comprises three different research areas (i.e., basic pharmacology, clinical pharmacology and pharmacy) with a very different number of journals in each area. 15 Additionally, journals such as Res Soc Admin Pharm are classified under different subject categories (indexed in two categories: Public, Environmental & Occupational Health; and in Social Sciences, Biomedical). Conversely, CiteScore and Scopus created a specific Pharmacy Subject Area, which includes 24 journals ranging from a 3.14 to a 0.00 CiteScore in the 2017 edition. Unfortunately, CiteScore also presents inconsistencies in the definition of the Subject Area. J Pharm Anal, an Elsevier journal with a declared scope about "all aspects of pharmaceutical analysis", is classified under six categories, including Pharmacy. However, Am J Health Syst Pharm is classified under Health Policy and under Pharmacology, or Eur J Hosp Pharm Sci Prac is classified under General Pharmacology, Toxicology and Pharmaceutics, but none of them are classified under Pharmacy. Unfortunately, due to the yearly update, these errors will not be corrected until the 2019 release of the 2018 CiteScore, and only then if we are able to convince Scopus managers. It seems that pharmacy practice researchers should devote efforts to describe clearly what pharmacy practice research is, and prioritizing pharmacy journals for their publications could be a required first step. 
